Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, 56266 [C1-2020-19209]

Download as PDF 56266 Federal Register / Vol. 85, No. 177 / Friday, September 11, 2020 / Notices provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Voice, Speech, and Language Application Review. Date: October 28, 2020. Time: 12:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NSC Building, 6001 Executive Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Sheo Singh, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, 6001 Executive Blvd., Room 8351, Bethesda, MD 20892, (301) 496–8683, singhs@ nidcd.nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Institutional Training Grant Review. Date: November 2, 2020. Time: 1:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, NSC Building, 6001 Executive Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Katherine Shim, Ph.D., Scientific Review Officer, Division of Extramural Activities, NIH/NIDCD, 6001 Executive Blvd., Room 8351, Bethesda, MD 20892, (301) 496–8683, katherine.shim@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS) Dated: September 8, 2020. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies In notice document 2020–19209, appearing on pages 54393–54394, in the issue of September 1, 2020, make the following corrections: 1. On page 54394, in the first column, in the fifteenth through twentieth lines: ‘‘Legacy Laboratory Services Toxicology, 1225 NE 2nd Ave, Portland, OR 97232, 503–413–5295/800–950– 5295, MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112, 651–636–7466/800–832–3244’’, should read: ‘‘Legacy Laboratory Services Toxicology, 1225 NE 2nd Ave, Portland, OR 97232, 503–413–5295/ 800–950–529 MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112, 651–636–7466/800–832–3244’’ 2. On the same page, in the same column, in the thirty-second through thirty-ninth lines: ‘‘Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888–635– 5840, Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)’’, should read: ‘‘Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888– 635–5840 Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)’’ [FR Doc. C1–2020–19209 Filed 9–10–20; 8:45 am] BILLING CODE 1301–00–D DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–7029–N–08] 60-Day Notice of Proposed Information Collection: Evaluation of Cohort 1 of the Moving to Work Demonstration Program Expansion Office of the Assistant Secretary for Policy Development and AGENCY: VerDate Sep<11>2014 20:54 Sep 10, 2020 Jkt 250001 The U.S. Department of Housing and Urban Development (HUD) is seeking approval from the Office of Management and Budget (OMB) for the information collection described below. In accordance with the Paperwork Reduction Act, HUD is requesting comment from all interested parties on the proposed collection of information. The purpose of this notice is to allow for 60 days of public comment. DATES: Comments Due Date: November 10, 2020. ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Anna P. Guido, Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 7th Street SW, Room 4176, Washington, DC 20410–5000; telephone 202–402–5534 (this is not a toll-free number) or email at Anna.P.Guido@hud.gov for a copy of the proposed forms or other available information. Persons with hearing or speech impairments may access this number through TTY by calling the tollfree Federal Relay Service at (800) 877– 8339. FOR FURTHER INFORMATION CONTACT: Anna P. Guido, Reports Management Officer, QDAM, Department of Housing and Urban Development, 451 7th Street SW, Washington, DC 20410; email Anna P. Guido at Anna.P.Guido@hud.gov or telephone 202–402–5535. This is not a toll-free number. Persons with hearing or speech impairments may access this number through TTY by calling the tollfree Federal Relay Service at (800) 877– 8339. Copies of available documents submitted to OMB may be obtained from Ms. Guido. SUPPLEMENTARY INFORMATION: This notice informs the public that HUD is seeking approval from OMB for the information collection described in Section A. SUMMARY: A. Overview of Information Collection [FR Doc. 2020–20094 Filed 9–10–20; 8:45 am] BILLING CODE 4140–01–P Research, Housing and Urban Development (HUD). ACTION: Notice. PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 Title of Information Collection: Evaluation of Cohort 1 of the Moving to Work Demonstration Program Expansion. OMB Approval Number: Pending. Type of Request: New collection. Form Number: NA. Description of the need for the information and proposed use: The Office of Policy Development and Research (PD&R), at the U.S. E:\FR\FM\11SEN1.SGM 11SEN1

Agencies

[Federal Register Volume 85, Number 177 (Friday, September 11, 2020)]
[Notices]
[Page 56266]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: C1-2020-19209]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of HHS-Certified Laboratories and Instrumented 
Initial Testing Facilities Which Meet Minimum Standards To Engage in 
Urine and Oral Fluid Drug Testing for Federal Agencies

    In notice document 2020-19209, appearing on pages 54393-54394, in 
the issue of September 1, 2020, make the following corrections:
    1. On page 54394, in the first column, in the fifteenth through 
twentieth lines:
    ``Legacy Laboratory Services Toxicology, 1225 NE 2nd Ave, Portland, 
OR 97232, 503-413-5295/800-950-5295, MedTox Laboratories, Inc., 402 W 
County Road D, St. Paul, MN 55112, 651-636-7466/800-832-3244'', should 
read:

``Legacy Laboratory Services Toxicology, 1225 NE 2nd Ave, Portland, OR 
97232, 503-413-5295/800-950-529
MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112, 
651-636-7466/800-832-3244''

    2. On the same page, in the same column, in the thirty-second 
through thirty-ninth lines:
    ``Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 
888-635-5840, Quest Diagnostics Incorporated, 1777 Montreal Circle, 
Tucker, GA 30084, 800-729-6432, (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories)'', should read:

``Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-
635-5840
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 
800-729-6432, (Formerly: SmithKline Beecham Clinical Laboratories; 
SmithKline Bio-Science Laboratories)''

[FR Doc. C1-2020-19209 Filed 9-10-20; 8:45 am]
BILLING CODE 1301-00-D